Principal TechnologiesFRA:JO7 4 PS Ratio is 44.00 as of Jul. 08, 2026, which is 450% above its 10-year median of 8.00. GuruFocus rates FRA:JO7 with a GF Score™ of 4/100 and a GF Value™ of €0.04 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 657 Healthcare Providers & Services companies, Principal Technologies ranks worse than 97.41% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Principal Technologies's share price is €0.22.
Principal Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was €0.01. Hence, Principal Technologies's PS Ratio for today is 44.00.
The historical rank and industry rank for Principal Technologies's PS Ratio or its related term are showing as below:
FRA:JO7'
s PS Ratio Range Over the Past 10 Years
Min: 5 Med: 8 Max: 86.25
Current: 47.5
During the past 6 years, Principal Technologies's highest PS Ratio was 86.25. The lowest was 5.00. And the median was 8.00.
FRA:JO7's PS Ratio is ranked worse than 97.41% of 657
companies
in the Healthcare Providers & Services industry
Industry Median: 1.5
vs FRA:JO7: 47.50
During the past 6 years, Principal Technologies's highest 3-Year average Revenue per Share Growth Rate was -22.00% per year. The lowest was -22.00% per year. And the median was -22.00% per year.
Back to Basics: PS Ratio
Principal Technologies (FRA:JO7) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Principal Technologies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Principal Technologies PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Principal Technologies's PS Ratio distribution charts can be found below:
* The bar in red indicates where Principal Technologies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Principal Technologies's Share Price of today is €0.22. Principal Technologies's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Principal Technologies (FRA:JO7) has a PS Ratio of 44.00 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Principal Technologies and its competitors. This is 450% above median its historical median of 8.00. Over the past decade, Principal Technologies' PS Ratio has ranged from 5.00 to 86.25. According to the industry distribution chart, Principal Technologies ranks #640 out of 657 companies in the Healthcare Providers & Services industry, placing it in the top 97.4%.
Is Principal Technologies' PS Ratio too high?
Principal Technologies' current PS Ratio of 44.00 is 450% above median its 10-year median of 8.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 86.25. The Healthcare Providers & Services industry median PS Ratio is 1.50. Principal Technologies' value of 44.00 is 2833.3% above this industry median. Based on the distribution chart, Principal Technologies ranks #640 out of 657 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Principal Technologies has a GF Score™ of 4/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Principal Technologies' PS Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Principal Technologies ranks #640 out of 657 companies for PS Ratio. This places Principal Technologies in the lower half of its industry. The industry median PS Ratio is 1.50. Principal Technologies' value of 44.00 is 2833.3% above this benchmark. Historically, Principal Technologies' own PS Ratio has ranged from 5.00 to 86.25 over the past decade. While the company's 10-year median is 8.00 vs. the industry median of 1.50, Principal Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.50, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Principal Technologies's current PS Ratio of 44.00 is 2833.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Principal Technologies and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Principal Technologies's current PS Ratio is 44.00, which is 450% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Principal Technologies stock overvalued right now?
Based on GuruFocus' analysis, Principal Technologies (FRA:JO7) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.04, compared to a current price of €0.22 — trading 450% above its estimated fair value. The current PS Ratio is 44.00, which is 450% above median its 10-year median of 8.00 and 2833.3% above the Healthcare Providers & Services industry median of 1.50. Principal Technologies' overall GF Score™ is 4/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Principal Technologies (FRA:JO7), the current PS Ratio is 44.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Principal Technologies (FRA:JO7) Overvalued in 2026?
Based on GuruFocus' analysis, Principal Technologies stock appears to be overvalued.
The current stock price of €0.22 is trading 450% above its estimated GF Value™ of €0.04.
GuruFocus considers Principal Technologies to be Significantly Overvalued.
Key valuation signals for FRA:JO7:
PS Ratio: 44.00 (450% above median its 10-year median of 8.00)
GF Value™: €0.04 vs. price of €0.22 (450% above fair value)
Industry Position: 2833.3% above the Healthcare Providers & Services median (#640 of 657)
No single metric tells the full story. See the FRA:JO7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Principal Technologies Inc is in the research and development stage of building a portfolio of medical technology assets with a focus on distribution potential and intellectual property capable of enhancing medical treatment, cost efficiency, and optimization of the patient pathway. The company focuses on acquiring medical technology research and development assets or developing them jointly with industry leaders. Its current revenue-generating activities are attributable to E&E CRO Consulting GmbH, which provides clinical research advisory services. The company operates in one reportable operational segment, consisting of project management of clinical studies and research related to medical device technologies.
4GF Score
Get the complete analysis for FRA:JO7
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:JO7 has been successfully added to your 
